We found that METTL1 expression was lower in responders than in non-responders to ICB therapy in breast, colorectal, ovarian cancer, and glioblastoma patients, suggesting that high METTL1 expression predicted poor response to ICB therapy (Fig. 7J). The gene discussed is METTL1; the disease is glioblastoma.